Global Literature Review
Maintain compliance and enhance safety oversight with expert-driven literature evaluation and reporting.
Literature Search
The review of worldwide scientific literature is an essential part of the ongoing safety surveillance of medicinal products, regardless of commercial status. To ensure compliance with regulatory legislation worldwide, it is essential that global and local literature screening, where applicable, is regularly conducted to identify reportable ICSRs and safety relevant information.
Our experienced team at ProPharma can support you or assume full responsibility for these activities to ensure your PV program adheres to the global regulatory requirements.
In addition, our services are cost-effective, and we are able to conduct global literature surveillance of large bibliographical databases including Medline® via the Biologit platform.
We have extensive experience in developing robust search strategies for our clients and providing results from these searches according to an agreed upon periodicity. We can perform the review and assessment of identified literature articles and ensure the efficient and auditable documentation of results.
We have experience and well-established processes for conducting local literature screenings. We can support you in the set-up and conduct, including the identification of relevant local databases and journals, and translation of articles, if needed.
For Marketing Authorization Holders (MAHs) with active substances included in the EMA’s Medical Literature Monitoring (MLM) list, we perform EudraVigilance checks using the ICSR Export module based on the frequency contracted. In addition, we provide local literature searches in relevant local scientific and medical journals in countries where your product is marketed and where this is legally required.
News & Insights
July 27, 2026
From Feasibility to First Patient In: Streamlining Study Start‑Up with Confidenc...
Discover how ProPharma streamlines clinical trial study start-up, ensuring predictable activation and reducing risks from feasibility to first patient in.cl
July 23, 2026
QMSR Explained: Key Changes from FDA QSR to the New Quality Management System Re...
The FDA's transition to the QMSR simplifies compliance, emphasizing risk management and aligning with global standards for medical devices compared to QMR.
July 8, 2026
ProPharma Advances Technology Enablement Strategy with AI-Assisted Capability fo...
ProPharma unveils an AI-assisted capability to enhance ANDA submission development, improving efficiency and maintaining regulatory excellence for clients.
June 18, 2026
ProPharma Welcomes Kevin van Dooren to Strengthen Integrated EU Regulatory and H...
ProPharma welcomes Kevin van Dooren as Vice President, HEOR and Market Access, strengthening integrated EU regulatory, HTA, reimbursement, and market access capabilities for life sciences companies.
January 31, 2025
ProPharma Recognized for AI Excellence at ECCCSA
ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.
October 9, 2024
ProPharma Receives 2024 CPHI Regulatory and Compliance Award
ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.
July 23, 2026
Inspection-Ready AI: Building Quality Frameworks That Keep Pace with Innovation
As artificial intelligence becomes increasingly embedded across life sciences, organizations face a growing challenge: ensuring quality and compliance frameworks evolve alongside rapidly advancing...
July 15, 2026
Ensuring Continuity of Neonatal Vitamin Prophylaxis During a Product Shortage: A...
Product shortages involving essential medicines can create significant clinical and regulatory challenges, particularly when vulnerable patient populations depend on uninterrupted access to...
June 17, 2026
Meeting Patients Where They Are: Delivering Global Clinical Support for Time-Sen...
Conducting clinical research for rare pediatric populations presents unique operational challenges, particularly when eligible patients may be born anywhere in the world and require immediate...
September 30, 2026
From Feasibility to First Patient In: How to Streamline Study Start-Up
Clinical trial delays often begin long before study conduct, with critical decisions made during feasibility and study start-up shaping the success of the entire trial. Join this webinar to discover...
June 4, 2026
Tech Meets Touch: Evaluating Empathy and AI in Medical Information Delivery
Artificial intelligence (AI) is a hot topic in Medical Information (MI), yet real-world evidence of its impact in regulated, human-led MI environments remains limited. Hear practical, evidence-based...
News & Insights
July 23, 2026
Inspection-Ready AI: Building Quality Frameworks That Keep Pace with Innovation
As artificial intelligence becomes increasingly embedded across life sciences, organizations face a growing challenge: ensuring quality and compliance frameworks evolve alongside rapidly advancing...
July 15, 2026
Ensuring Continuity of Neonatal Vitamin Prophylaxis During a Product Shortage: A...
Product shortages involving essential medicines can create significant clinical and regulatory challenges, particularly when vulnerable patient populations depend on uninterrupted access to...
June 17, 2026
Meeting Patients Where They Are: Delivering Global Clinical Support for Time-Sen...
Conducting clinical research for rare pediatric populations presents unique operational challenges, particularly when eligible patients may be born anywhere in the world and require immediate...